1. |
Specht J, Gralow JR. Neoadjuvant chemotherapy for locally advanced breast cancer [J]. Semin Radiat Oncol, 2009; 19(4): 222228.
|
2. |
Dowsett M, Procter M, McCaskillStevens W, et al. Diseasefree survival according to degree of HER2 amplification for patients treated with adjuvant chemotherapy with or without 1 year of trastuzumab: the HERA Trial [J]. J Clin Oncol, 2009; 27(18): 29622969.
|
3. |
Clavarezza M, Venturini M. Adjuvant chemotherapy for the treatment of HER2positive early breast cancer [J]. Oncology, 2009; 77 Suppl 1: 1417.
|
4. |
Kang H, Watkins G, DouglasJones A,et al. The elevated level of CXCR4 is correlated with nodal metastasis of human breast cancer [J]. Breast, 2005; 14(5): 360367.
|
5. |
Huang EH, Singh B, Cristofanilli M, et al. A CXCR4 antagonist CTCE9908 inhibits primary tumor growth and metastasis of breast cancer [J]. J Surg Res, 2009; 155(2): 231236.
|
6. |
Eisenhauer EA, Therasse P, Bogaerts J, et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1) [J]. Eur J Cancer, 2009; 45(2): 228247.
|
7. |
Ogston KN, Miller ID, Payne S, et al. A new histological grading system to assess response of breast cancers to primary chemotherapy: prognostic significance and survival [J]. Breast, 2003; 12(5): 320327.
|
8. |
Mayr D, Heim S, Werhan C, et al. Comprehensive immunohistochemical analysis of Her2/neu oncoprotein overexpression in breast cancer: HercepTest (Dako) for manual testing and Her2/neuTest 4B5 (Ventana) for Ventana BenchMark automatic staining system with correlation to results of fluorescence in situ hybridization (FISH) [J]. Virchows Arch, 2009; 454(3): 241248.
|
9. |
Kato M, Kitayama J, Kazama S, et al. Expression pattern of CXC chemokine receptor4 is correlated with lymph node metastasis in human invasive ductal carcinoma [J]. Breast Cancer Res, 2003; 5(5): R144R150.
|
10. |
Wang CJ, Zhou ZG, Holmqvist A, et al. Survivin expression quantified by Image ProPlus compared with visual assessment [J]. Appl Immunohistochem Mol Morphol, 2009; 17(6): 530535.
|
11. |
陶金波, 康骅, 海涛, 等. 基质细胞衍生因子1在乳腺癌肿瘤患者血浆中的表达及其临床意义 [J]. 中国普外基础与临床杂志, 2008; 15(12): 914916.
|
12. |
康骅, Mansel RE, Jiang WG. 基质细胞衍化因子1的表达及其与乳腺癌患者预后的关系 [J]. 中国普外基础与临床杂志, 2005; 12(5): 483487.
|
13. |
Kang H, Watkins G, Parr C, et al. Stromal cell derived factor1: its influence on invasiveness and migration of breast cancer cells in vitro, and its association with prognosis and survival in human breast cancer [J]. Breast Cancer Res, 2005; 7(4): R402R410.
|
14. |
Müller A, Homey B, Soto H, et al. Involvement of chemokine receptors in breast cancer metastasis [J]. Nature, 2001; 410(6824): 5056.
|
15. |
Richert MM, Vaidya KS, Mills CN, et al. Inhibition of CXCR4 by CTCE9908 inhibits breast cancer metastasis to lung and bone [J]. Oncol Rep, 2009; 21(3): 761767.
|
16. |
Mirisola V, Zuccarino A, Bachmeier BE, et al. CXCL12/SDF1 expression by breast cancers is an independent prognostic marker of diseasefree and overall survival [J]. Eur J Cancer, 2009; 45(14): 25792587.
|
17. |
黄桂林, 张剑权, 吴毅平, 等. 新辅助化疗对乳腺癌患者胰岛素样生长因子1受体表达的影响. [J]. 中国普外基础与临床杂志, 2009; 16(10): 834837.
|
18. |
Fernandes RC, Bevilacqua JL, Soares IC, et al. Coordinated expression of ER, PR and HER2 define different prognostic subtypes among poorly differentiated breast carcinomas [J]. Histopathology, 2009; 55(3): 346352.
|
19. |
Safwat MD, Habib F, Elayat A, et al. Morphometric and immunohistochemical study of angiogenic marker expressions in invasive ductal carcinoma of human breast [J]. Folia Morphol (Warsz), 2009; 68(3): 144155.
|
20. |
Stroescu C, Dragnea A, Ivanov B, et al. Expression of p53, Bcl2, VEGF, Ki67 and PCNA and prognostic significance in hepatocellular carcinoma [J]. J Gastrointestin Liver Dis, 2008; 17(4): 411417.
|
21. |
Jones RL, Salter J, A’Hern R, et al. The prognostic significance of Ki67 before and after neoadjuvant chemotherapy in breast cancer [J]. Breast Cancer Res Treat, 2009; 116(1): 5368.
|
22. |
Lu DY, Tang CH, Yeh WL, et al. SDF1 upregulates interleukin6 through CXCR4, PI3K/Akt, ERK, and NFκBdependent pathway in microglia [J]. Eur J Pharmacol, 2009; 613(13): 146154.
|
23. |
Yuan Y, Kan H, Fang Q, et al. CXCR4 receptor antagonist blocks cardiac myocyte p38 MAP kinase phosphorylation by HIV gp120 [J]. Cardiovasc Toxicol, 2008; 8(4): 173180.
|
24. |
Sengupta N, Afzal A, Caballero S, et al. Paracrine modulation of CXCR4 by IGF1 and VEGF: implications for choroidal neovascularization [J]. Invest Ophthalmol Vis Sci, 2009; 51(5): 26972704.
|
25. |
Robinson BD, Jones JG. Tumor microenvironment of metastasis (TMEM): a novel tissuebased assay for metastatic risk in breast cancer [J]. Future Oncol, 2009; 5(7): 919921.
|
26. |
Sund M, Kalluri R. Tumor stroma derived biomarkers in cancer [J]. Cancer Metastasis Rev, 2009; 28(12): 177183.
|
27. |
Xouri G, Christian S. Origin and function of tumor stroma fibroblasts [J]. Semin Cell Dev Biol, 2009; 21(1): 4046.
|